Core Insights - INVL Baltic Sea Growth Fund has completed the acquisition of Pehart Group, a leading Romanian producer of household and industrial paper products, with a financing package exceeding EUR 150 million [1][4] - The investment aims to enhance Pehart Group's manufacturing capacities and support its expansion in the region, reinforcing its market leadership [3][8] - Pehart Group generated revenues of EUR 165 million in 2024 and employs over 550 people, indicating its significant presence in the Southeast European paper manufacturing market [8] Investment Details - The financing for the transaction was provided by a consortium including International Finance Corporation (IFC), Banca Transilvania, and ING Bank Romania [1][4] - The deal was finalized on July 11, 2023, marking a transition from Abris Capital Partners to INVL Baltic Sea Growth Fund [2][3] - The investment includes a sustainable linked component, aligning with IFC's commitment to fostering sustainable economic growth in Romania [5] Company Strategy - Pehart Group plans to invest in cutting-edge technologies, diversify its product portfolio, and expand its international market presence [3][8] - The company has launched new products, such as the SOVIO brand targeting the Away-from-Home sector, reflecting its strategy to diversify offerings [8][9] - The partnership with INVL Baltic Sea Growth Fund is seen as an opportunity to accelerate Pehart Group's development plans and strengthen its regional leadership [3][6] Fund Overview - INVL Baltic Sea Growth Fund is the leading private equity fund in the Baltics, with a fund size of EUR 165 million and managed by Invalda INVL group [10] - The fund has a strong backing from the European Investment Fund (EIF) and aims to support high-growth potential small and medium-sized enterprises in the region [10]

Core Viewpoint - Falcon Oil & Gas Ltd has announced a significant achievement in the Beetaloo Sub-basin with the Shenandoah S2-2H ST1 well achieving an average 60-day initial production (IP60) flow rate of 6.8 million cubic feet per day (MMcf/d), marking the highest IP60 result in the region to date [2][5]. Drilling Campaign - The 2025 drilling campaign has commenced, which is the largest drilling initiative in the Beetaloo to date, targeting up to three 10,000-foot horizontal wells to be drilled back-to-back over the next few months [6][8]. - This campaign aims to provide further evidence of the commercial potential of the Beetaloo Sub-basin [6]. Production Results - The average flow rate of 12.4 MMcf/d over a normalized 10,000-foot horizontal section aligns with the average of over 11,000 wells in the Marcellus Shale dry gas area over a 12-month period, indicating strong commercial deliverability of gas from the Beetaloo to the Australian domestic East Coast gas market [8]. - The exit rate maintains a steady, low-declining curve at 6.4 MMcf/d with a flowing wellhead pressure of approximately 720 psi, showing less decline compared to the Shenandoah South 1H well over the last 30 days of testing [8]. Company Insights - Falcon Oil & Gas Ltd is focused on the exploration and development of unconventional oil and gas assets, with its current portfolio primarily in Australia [10]. - Falcon Australia has opted to reduce its participating interest in the three wells to 0%, resulting in no cost exposure to the drilling of these wells [8].

EUROCASTLE INVESTMENT LIMITED FOR IMMEDIATE RELEASEContact: Oak Fund Services (Guernsey) LimitedCompany AdministratorAttn: Nicole BarnesTel: +44 1481 723450 Eurocastle Announces Posting of 2025 Annual General Meeting Notice Guernsey, 14 July 2025 – Eurocastle Investment Limited (Euronext Amsterdam: ECT) (“Eurocastle” or the “Company”) today announces that notice of its Annual General Meeting containing the full text of the proposed resolutions and a proxy statement has been mailed out to all holders on r ...

NTG Nordic Transport Group A/S – H1 2025 Conference Call We expect to release the H1 2025 interim results of NTG Nordic Transport Group on the evening of August 11, 2025. A webcast and conference call will be held in the morning of August 12, 2025, at 10:00 am CET. At the call, Group CEO Mathias Jensen-Vinstrup and Group CFO Christian D. Jakobsen will present the H1 2025 Interim Financial Report. The presentation will be followed by a Q&A session. Date: August 12, 2025Time: 10:00 am CET To attend the confe ...

Core Viewpoint - Serabi Gold plc reported strong production results for Q2 2025, achieving the highest quarterly output since operations resumed in 2013, with a total of 10,532 ounces of gold produced, marking a 17% increase compared to Q2 2024 [3][4][7]. Production Highlights - Total gold production for the year-to-date (YTD) reached 20,545 ounces, slightly above budget and on track with guidance [3][7]. - The Palito plant feed grades improved by 27% year-to-date compared to the 2024 average, while Coringa's grades improved by 12% [4]. - The company completed over 3,850 meters of horizontal development in Q2 2025, a 10% increase from Q1 2025, marking the highest quarterly development since operations began [7][15]. Financial Performance - Cash balance as of June 30, 2025, was $30.4 million, up from $26.5 million at the end of Q1 2025, with a net cash balance of $24.6 million after liabilities [7][16]. - The company remains on track to achieve its 2025 consolidated production guidance of 44,000 to 47,000 ounces of gold [17]. Exploration and Development - Initial results from brownfield exploration at the Palito Complex, Coringa Mine, and São Domingos target showed promising grades, with several drill holes reporting high gold concentrations [10][7]. - The company is targeting approximately 30,000 meters of drilling this year, with two rigs operating at both Palito and Coringa [10]. Operational Insights - The Coringa mine has shown strong performance, with production from both the Serra and Meio zones, and development activities are ongoing [6][15]. - The Palito Complex has seen significant grade improvements, with mined grades averaging approximately 6.19 g/t gold year-to-date compared to 4.86 g/t in 2024 [9].

Core Points - VERSES AI Inc. has successfully closed a public offering of 1,007,764 units at a price of C$9.50 (US$6.946) per unit, raising gross proceeds of approximately C$9,573,758 (US$7,000,331) [1][3] - Each unit consists of one Class A Subordinate Voting Share and one-half of a Share purchase warrant, with the warrant allowing the purchase of one share at an exercise price of C$11.50 (US$8.409) for 36 months [2] - The net proceeds from the offering will be used to strengthen the company's financial position, support ongoing operations, and fund research and development objectives [3] Financial Details - The company paid a cash commission of C$450,000 to the agents and issued 35,271 compensation warrants, each exercisable into a share at C$11.50 (US$8.409) [4] - Additionally, a cash fee of US$250,000 (C$341,904) was paid to a financial advisor, along with the issuance of 75,000 corporate finance fee warrants with identical terms to the compensation warrants [4] Regulatory Information - The offering was completed in Canada under a prospectus supplement and was filed with securities commissions across Canada, except Quebec, and with the U.S. SEC [5] - The offering was conducted in the U.S. under a registration statement declared effective by the SEC, which includes the base shelf prospectus [5][7]

Core Insights - Crinetics Pharmaceuticals announced new data on PALSONIFY (paltusotine) for acromegaly, highlighting its potential as a next-generation treatment option with a consistent safety profile and durable IGF-1 control [2][9] Group 1: Clinical Data and Results - The PATHFNDR-1 trial showed that 53 out of 58 participants (91%) entered the ongoing open-label extension after a 36-week randomized, placebo-controlled period, with interim analysis data available through Week 96 [3] - In the PATHFNDR-2 trial, 103 of 106 completers (97.2%) transitioned to the ongoing open-label extension after a 24-week randomized controlled period, with efficacy data from 88 patients through Week 84 [5] - Mean IGF-1 levels remained stable at 0.81 ± 0.21 times the upper limit of normal (ULN) at Week 96, demonstrating durable biochemical control [6][7] Group 2: Symptom Control and Patient Outcomes - Patients switching from injected somatostatin receptor ligands (SRLs) to PALSONIFY experienced a significant reduction in symptom exacerbations, from over 30% of days on SRLs to just 6.2% during stable PALSONIFY dosing (p < 0.0001) [8] - A pooled analysis of Acromegaly Symptom Diary (ASD) scores indicated that a greater proportion of patients treated with PALSONIFY reported less symptom burden compared to those on placebo [8] Group 3: Company Overview and Future Prospects - Crinetics Pharmaceuticals is focused on developing novel therapeutics for endocrine diseases, with PALSONIFY being the first investigational once-daily oral SST2 nonpeptide agonist in Phase 3 clinical development for acromegaly and carcinoid syndrome [9][10] - The company is also developing Atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, with all drug candidates being orally delivered small molecules [10]

Core Insights - Rhythm Pharmaceuticals presented new data on acquired hypothalamic obesity at the Endocrine Society's Annual Meeting (ENDO 2025), highlighting the efficacy of setmelanotide and bivamelagon in reducing body mass index (BMI) in affected patients [1][2][3]. Group 1: Clinical Data and Efficacy - The Phase 2 SIGNAL trial demonstrated that bivamelagon, a daily oral MC4R agonist, achieved statistically significant and clinically meaningful reductions in BMI over 14 weeks [2]. - The Phase 3 TRANSCEND trial showed setmelanotide resulted in a -9.3% BMI reduction in the 600mg cohort, -7.7% in the 400mg cohort, and -2.7% in the 200mg cohort, with a placebo cohort showing a 2.2% increase in BMI [4][5]. - A placebo-adjusted difference of -19.8% in BMI reduction was observed across 120 participants, with significant reductions noted in various age and sex subgroups [5][6]. Group 2: Patient Impact and Future Potential - The data from the trials suggest that both bivamelagon and setmelanotide could become transformative therapeutic options for patients with acquired hypothalamic obesity, potentially establishing a new standard of care [2][4]. - Rhythm estimates that there are between 5,000 to 10,000 individuals living with hypothalamic obesity in the U.S., indicating a significant patient population that could benefit from these treatments [11]. Group 3: Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, with its lead asset, setmelanotide, approved for treating obesity related to specific genetic conditions [9][12]. - The company is advancing a broad clinical development program for setmelanotide and other investigational MC4R agonists, indicating a commitment to expanding treatment options for patients with rare diseases [9].

Core Insights - The 2025 Xiamen Talent Service Month aims to attract global talent to foster innovation and development in the city [1][2] - The event emphasizes practical matchmaking between talent and enterprises, focusing on technological achievements [2] Talent Initiatives - Xiamen has established global talent workstations to facilitate the flow of international professionals, including the "Heart Sapling Visiting Scholar Program" by Xiamen Cardiovascular Hospital [3] - The program has formed strategic partnerships with leading medical institutions in six countries, attracting 26 young physicians for training [4] Policy and Support - Xiamen introduced the "Eight-point Policy on AI Industry Talent Development" to enhance support for professionals in key areas such as recruitment and cultivation [5] - The "Top 10 AI+Talent Application Scenarios" were also introduced, aligning AI technologies with talent services in various sectors [6] International Engagement - Xiamen has hosted overseas entrepreneurship competitions for seven consecutive years, enhancing its global talent attraction [7] - The inaugural Global Innovation and Entrepreneurship Competition seeks leading talent projects in innovative fields, with over 300 projects registered from nearly 20 countries [8]

Group 1 - Galway Metals Inc. intends to settle the final payment of $125,000 in cash and issue 974,026 common shares at a deemed price of $0.385 per share, totaling $375,000 [1][2] - The company previously agreed to buy back a 2% net smelter returns royalty for a total purchase price of $3,000,000, to be paid in six equal annual installments of $500,000 [2] - The first partial payment was settled in 2020 through the issuance of 434,783 shares at a deemed price of $1.15 per share [2] Group 2 - Galway Metals is focused on creating significant per share value through the exploration and sustainable development of its two 100%-owned projects in Canada [3] - The flagship project, Clarence Stream, is a major gold district in Atlantic Canada with a large, high-grade gold resource [3] - The Estrades project is a former high-grade gold and zinc-rich polymetallic VMS mine located in western Quebec [3]